Austar Lifesciences Limited provided consolidated earnings guidance for the year ended 31 December 2022. It is expected that a profit attributable to the owners of the Company of not less than RMB 50 million will be recorded for the year ended 31 December 2022, as compared with that of approximately RMB 277.3 million for the year ended 31 December 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.82 HKD | -7.87% | -18.00% | -47.44% |
Mar. 26 | Austar Lifesciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 22 | Austar Lifesciences to Swing to Loss; Shares Drop | MT |
1st Jan change | Capi. | |
---|---|---|
-47.44% | 53.69M | |
-2.31% | 187B | |
-3.20% | 106B | |
-5.04% | 66.9B | |
+0.20% | 49.45B | |
+17.29% | 48B | |
+4.06% | 40.84B | |
+2.07% | 26.48B | |
+2.36% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- 6118 Stock
- News Austar Lifesciences Limited
- Austar Lifesciences Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022